摘要
目的利用组织芯片技术,结合免疫组化方法,研究上皮生长因子受体(epidermalgrowthfactorreceptor,EGFR)在非小细胞肺癌的免疫组化表达及其对生存率的影响。方法303例非小细胞肺癌石蜡标本制成组织芯片,采用链菌素亲生物素-过氧化物酶法(SP)进行免疫组化检测,并用SPSS9.0统计软件进行χ2检验和生存分析。结果EGFR阳性表达171例(56.4%),阴性表达132例(43.6%)。有淋巴结转移组的EGFR表达阳性率为62.7%,无淋巴结转移组的48.9%(P<0.05)。鳞癌的EGFR表达阳性率55.6%,腺癌的EGFR表达阳性率58.8%(P>0.05)。EGFR阳性表达组与阴性表达组的生存率比较没有显著性差异(P>0.05)。结论(1)利用组织芯片技术,结合免疫组化可以大规模、快速高效地检测EGFR在非小细胞肺癌组织的表达。(2)非小细胞肺癌有淋巴结转移组的EGFR过表达明显高于没有淋巴结转移组。(3)EGFR过表达对非小细胞肺癌的预后没有影响。
Objective To investigate the epidermal growth factor receptor (EGFR) immunohistochemical expression in patients with non small cell lung cancer (NSCLC) using tissue microarray technique.Methods 303 NSCLC specimens were constructed into tissue microarray and stained with monoclonal antibodies against EGFR.Results EGFR over expression were shown in 171 cases ( 56.4% ). 62.7% cases with lymph node metastasis shown over expression, while only 48.9% in without lymph node metastasis. 55.6% cases of squamous cell carcinoma were over expression and 58.8% in adenocarcinoma. None of the tested parameters was significant in univariate survival analysis.Conclusion (1) With tissue microarray technique, investigation of EGFR immunohistochemical expression in NSCLC can be done in a large scale and finished in a short time. (2) EGFR over expression is obviously higher in NSCLC with lymph node metastasis than without lymph node metastasis. (3) No significant difference in NSCLC survival with EGFR over expression.
出处
《肿瘤防治研究》
CAS
CSCD
2004年第11期671-673,共3页
Cancer Research on Prevention and Treatment
基金
广州市科技局重点攻关项目(2001-Z-044-01)
广东省重点医学科技攻关专项课题(WSTJJ20030726440102560203401)
关键词
肺肿瘤
组织芯片
免疫组化
EGFR
Lung neoplasm
Tissue microarray
Immunohistochemistry
EGFR
